FDA Enforcement Powers Remain In Limbo As User Fee Bill Glides Through Markup
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate committee approves comprehensive user fee bill, but FDA authority to destroy some unsafe drug imports and track-and-trace provisions remain outstanding issues. Meanwhile, the House is going back to the drawing board on several provisions.
You may also be interested in...
Track And Trace System Could Start With RxTEC As Foundation, FDA Says
Compromise proposal from agency would allow lot-level tracking at first, if there was a “clear path” to a more advanced system in subsequent years.
PDUFA Stars Aligning As House Draft Gives FDA Direct Authority Over Importers
Latest version of potential House user fee bill eliminates revisions to FDA’s mission statement and includes provisions for approving breakthrough technologies and destroying unsafe drug imports at the border.
On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues
As FDA prepares for another public hearing on the pathway, FTC says the rules requiring biosimilar applicants to share information with their reference product competitors could lead to anti-competitive issues and may be an ongoing concern.